FDA Clearance Tracker · P060038-S020
MITROFLOW AORTIC PERICARDIAL HEART VALVE WITH PHOSPHOLIPID REDUCTION TREATMENT, MODEL DL
Last checked: Nov 20, 2026Latest source record: Jul 15, 2014 (this decision)Source: openFDAMethods & limitations
Decided
Jul 15, 2014
Approved
Time to decision
60 days
Received May 16, 2014. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P060038-S020
- Device name
- MITROFLOW AORTIC PERICARDIAL HEART VALVE WITH PHOSPHOLIPID REDUCTION TREATMENT, MODEL DL
- Applicant
- Corcym Canada Corp
- Applicant location
- Burnaby
- Received
- May 16, 2014
- Decided
- Jul 15, 2014
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol - OSB
- Original approval
- P060038
Device type
- Device type
- heart-valve, non-allograft tissue (LWR)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL OF THE POST-APPROVAL STUDY PROTOCOL.
Source documents
Other decisions for Corcym Canada Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.